Hairy cell leukemia: a B cell neoplasm with a unique antigenic phenotype

American Journal of Clinical Pathology
S M HsuE S Jaffe

Abstract

A panel of B, T, and monocyte antibodies was used to study the phenotype of hairy cell leukemia. It was found that the neoplastic cells had monoclonal surface immunoglobulins and, in addition, reacted with B1, HLA-DR, Leu 10, and Tac. Most of the above markers are features of B cell lymphocytes. However, Tac is a monoclonal antibody normally reactive with activated T lymphocytes. All other antibodies reactive with T cells were negative. An additional unexpected finding was intranuclear reactivity in 4/5 cases with an antibody to TdT. TdT enzymatic activity was not demonstrable by biochemical assay. All five cases were nonreactive with monocyte antibodies. The findings support the concept that hairy cell leukemia is of B cell lineage but demonstrates an unusual phenotype not seen in other normal or neoplastic B lymphocytes.

Citations

Apr 1, 1991·Cancer·J D TempleC B McCoy
Nov 15, 1985·Cancer·K M DavisR C Braylan
Mar 1, 1986·Cytometry·D R van BockstaeleM E Peetermans
Jun 12, 2003·Current Opinion in Hematology·Grant R GoodmanAlan Saven
Apr 10, 2004·Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc·Naoyoshi MoriToshiro Nagasawa
May 1, 1985·Hepatology : Official Journal of the American Association for the Study of Liver Diseases·M L RoquetY Pinaudeau
Jan 1, 1988·Cancer·G De PanfilisP Sansoni
Sep 1, 1992·Annals of Hematology·E WeeksP A Bunnell
Mar 8, 2000·Leukemia & Lymphoma·S A TetreaultA Saven
Jan 1, 1989·Critical Reviews in Oncology/hematology·B FaliniM F Martelli
Jan 1, 1987·Critical Reviews in Oncology/hematology·J Jansen

❮ Previous
Next ❯

Related Concepts

Related Feeds

B-Cell Leukemia (Keystone)

B-cell leukemia includes various types of lymphoid leukemia that affect B cells. Here is the latest research on B-cell leukemia.

B-Cell Lymphoma

B-cell lymphomas include lymphomas that affect B cells. This subtype of cancer accounts for over 80% of non-Hodgkin lymphomas in the US. Here is the latest research.